| Symbol | ADCT |
|---|---|
| Name | ADC THERAPEUTICS SA |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | BIOPLE,ROUTE DE LA CORNICHE 3B, EPALINGES, 1066, Switzerland |
| Telephone | +41 21 - 653 02 00 |
| Fax | — |
| — | |
| Website | https://www.adctherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001771910 |
| Description | ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The companys product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Additional info from NASDAQ: |
Zaki Mohamed 🟢 acquired 213.9K shares of ADC Therapeutics SA (ADCT) Transaction Date: Jun 30, 2026 | Filing ID: 047036
Read moreGRAHAM PETER J 🟢 acquired 221.1K shares of ADC Therapeutics SA (ADCT) Transaction Date: Jun 30, 2026 | Filing ID: 047034
Read moreCarmona Jose 🟢 acquired 203.7K shares of ADC Therapeutics SA (ADCT) Transaction Date: Jun 30, 2026 | Filing ID: 047033
Read moreDirector MALLIK AMEET 🟢 acquired 675.0K shares of ADC Therapeutics SA (ADCT) Transaction Date: Jun 30, 2026 | Filing ID: 047031
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Read moreDirector Azelby Robert 🟡 adjusted position in 32.4K shares of ADC Therapeutics SA (ADCT) at $3.08 Transaction Date: Jun 01, 2026 | Filing ID: 040493
Read more